Originally developed for the treatment of BCR/ABL positive chronic myeloid leukemia, gleevec is also effective for several constitutively active mutations of c-kit found in numerous t(8;21) positive patients [34]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.